HETEROCYCLIDENE DERIVATIVE HAVING P-SUBSTITUTED ARYLACETAMIDE

WIPO Patent Application WO/2010/010934

A1

Disclosed are: a compound represented by formula (I) [wherein m represents a number of 0 to 2; n represents a number of 1 or 2; p represents a number of 0 to 2; q represents a number of 0 or 1; R1 represents a halogen, a C1-2 alkyl, or the like; R2 represents a halogen, a C1-5 (substituted) alkyl, or the like; R3 represents a hydrogen atom, a halogen, a (halogen-substituted) C1-6 alkyl, or the like; X1 represents O or -NR6-; X2 represents a methylene, O or -NH-; Y represents a single bond, or a (halogen-substituted) C1-4 alkylene group; G1 and G2 independently represent N or C-R7; and the moiety represented by "Cycle" represents a 5- to 6-membered aryl which may have one or two members selected from N, O and S], a salt of the compound, or a solvate of the compound or the salt; and a pharmaceutical composition and a TRPV1 receptor modulator each comprising the compound, the salt or the solvate as an active ingredient.

WO/2001/066108	INHIBITION OF CERAMIDE FOR THE PREVENTION AND TREATMENT OF ORAL MUCOSITIS INDUCED BY ANTINEOPLASTIC DRUGS OR RADIATION
WO/2001/014365	COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING bcl-2 FAMILY MEMBER PROTEINS
WO/1994/013654	NOVEL TAXOIDS, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

MATSUNAGA ATSUO (JP)
UCHIDA HIDEHARU (JP)
MAEDA YOSHITAKA (JP)

PCT/JP2009/063218

January 28, 2010

July 23, 2009

Click for automatic bibliography generation  

MOCHIDA PHARM CO LTD (JP)
MATSUNAGA ATSUO (JP)
UCHIDA HIDEHARU (JP)
MAEDA YOSHITAKA (JP)

A61K31/335; A61K31/35; A61K31/353; A61P21/00; A61P25/04; A61P29/00; A61P43/00; C07D311/58; C07D313/08

WO2007010383A1	2007-01-25
WO2008091021A1	2008-07-31

SWANSON, D.M. ET AL.: "Identification and biological evaluation of 4- (3-trifluoromethylpuridine-2-yl)piperazine-1- carboxylic acid (5-triffluoromethylpyridine-2- yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist", J. MED. CHEM., vol. 48, no. 6, 2005, pages 1857 - 1872
GAVVA, N. R. ET AL.: "The vanilliod receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation", J. NEUROSCI., vol. 27, no. 13, 2007, pages 3366 - 3374
LEHTO, S.G. ET AL.: "Antihyperalgesic effects of (R, E)-N-(2-hydroxy-2, 3-dihydro-lH-inden-4-yl)- 3-(2-piperidin-1-yl)-4-(trifluoromethyl)phenyl)- acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats", J. PHAMRACOL. EXP. THER., vol. 326, no. 1, 2008, pages 218 - 229

HANABUSA, Tsuneo et al. (JP)
Sepal Tsuneo (JP)

View/Download PDF      PDF Help

Previous Patent: HETEROCYCLIDENE-N-(3,4-DIHYDRO-2(1H)-QUINAZOLIN-5-YL) ACETAMIDE DERIVATIVE

Next Patent: OPTICALLY ACTIVE HETEROCYCLIDENE-N-ARYLACETAMIDE DERIVATIVE